4.8 Article

Cooperative Binding of Transcription Factors Orchestrates Reprogramming

期刊

CELL
卷 168, 期 3, 页码 442-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2016.12.016

关键词

-

资金

  1. Leukemia and Lymphoma Research [10040]
  2. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC) at UCLA
  3. UCLA
  4. NIH [R01ES024995, U01HG007912, P01-GM099134]
  5. NSF [1254200]
  6. Sloan Fellowship
  7. BSCRC
  8. David Geffen School of Medicine
  9. Jonnson Comprehensive Cancer Center at UCLA, CIRM
  10. CIRM [TG2-01169]
  11. Div Of Biological Infrastructure
  12. Direct For Biological Sciences [1254200] Funding Source: National Science Foundation

向作者/读者索取更多资源

Oct4, Sox2, Klf4, and cMyc (OSKM) reprogram somatic cells to pluripotency. To gain a mechanistic understanding of their function, we mapped OSKM-binding, stage-specific transcription factors (TFs), and chromatin states in discrete reprogramming stages and performed loss-and gain-of-function experiments. We found that OSK predominantly bind active somatic enhancers early in reprogramming and immediately initiate their inactivation genome-wide by inducing the redistribution of somatic TFs away from somatic enhancers to sites elsewhere engaged by OSK, recruiting Hdac1, and repressing the somatic TF Fra1. Pluripotency enhancer selection is a stepwise process that also begins early in reprogramming through collaborative binding of OSK at sites with high OSK-motif density. Most pluripotency enhancers are selected later in the process and require OS and other pluripotency TFs. Somatic and pluripotency TFs modulate reprogramming efficiency when overexpressed by altering OSK targeting, somatic-enhancer inactivation, and pluripotency enhancer selection. Together, our data indicate that collaborative interactions among OSK and with stage-specific TFs direct both somatic-enhancer inactivation and pluripotency-enhancer selection to drive reprogramming.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据